GlassScriptPhysician profile
Scott Anderson
NPI 1366403479
$15,175.69
in general payments reported to CMS, 2019-2025
59 companies · $2,361 in 2025
The $2,361 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,167 · 2020: $1,600 · 2021: $1,892 · 2022: $2,375 · 2023: $2,509 · 2024: $2,272 · 2025: $2,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,062 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,062.17 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,857.52 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $1,370.83 | 2019-2025 | |
| Amgen INC. | $1,362.64 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $1,311.81 | 2019-2025 | Ubrelvy, Qulipta, Linzess |
| Glaxosmithkline, LLC. | $994.97 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $952.83 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $834.82 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Antares Pharma, INC. | $575.70 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $422.08 | 2019-2025 | Xifaxan, Trulance |
| Horizon Therapeutics Plc | $414.70 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $360.66 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $354.70 | 2019-2023 | Trintellix |
| Amarin Pharma, INC. | $322.07 | 2019-2022 | |
| Exact Sciences Corporation | $318.80 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $316.34 | 2019-2024 | Veozah |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.